Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro.

Emil ChteinbergSuzan WetzelsWouter GerritsenLieve TemmermanJoost van den OordErik BiessenAnna Kordelia KurzVéronique WinnepenninckxMartin ZenkeErnst-Jan SpeelAxel Zur Hausen

Published in: Therapeutic advances in medical oncology (2020)

Our results show that the anti-apoptotic BCL-2 is frequently expressed in MCC and MCC cell lines. Inhibition of BCL-2 by Navitoclax in combination with Alpelisib revealed a strong synergy and prolonged inhibition of MCC cell viability and induction of apoptosis. The combination of Navitoclax and Alpelisib is a novel potential treatment option for MCC patients.

Keyphrases

end stage renal disease
cell death
ejection fraction
newly diagnosed
oxidative stress
peritoneal dialysis
endoplasmic reticulum stress
prognostic factors
cell cycle arrest
risk assessment
signaling pathway